Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Assessing uptake of the Harmonising Outcome Measures for Eczema (HOME) Core Outcome Set and Recommended Instruments.

Vincent R, Chalmers JR, McWilliams C, Thomas KS, Dodd S, Rogers N, Ridd MJ, Schmitt J, Kirkham JJ.

Br J Dermatol. 2020 Mar 13. doi: 10.1111/bjd.19030. [Epub ahead of print]

PMID:
32167583
2.

Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial.

Chalmers JR, Haines RH, Bradshaw LE, Montgomery AA, Thomas KS, Brown SJ, Ridd MJ, Lawton S, Simpson EL, Cork MJ, Sach TH, Flohr C, Mitchell EJ, Swinden R, Tarr S, Davies-Jones S, Jay N, Kelleher MM, Perkin MR, Boyle RJ, Williams HC; BEEP study team.

Lancet. 2020 Mar 21;395(10228):962-972. doi: 10.1016/S0140-6736(19)32984-8. Epub 2020 Feb 19.

3.

An algorithm for diagnosing IgE-mediated food allergy in study participants who do not undergo food challenge.

Kelleher MM, Jay N, Perkin MR, Haines RH, Batt R, Bradshaw LE, Montgomery AA, Chalmers JR, Williams HC, Boyle RJ.

Clin Exp Allergy. 2020 Mar;50(3):334-342. doi: 10.1111/cea.13577. Epub 2020 Feb 13.

PMID:
31999862
4.

Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative.

Leshem YA, Chalmers JR, Apfelbacher C, Furue M, Gerbens LAA, Prinsen CAC, Schmitt J, Spuls PI, Thomas KS, Williams HC, Simpson EL; Harmonising Outcome Measures for Eczema (HOME) initiative.

J Am Acad Dermatol. 2020 Jan 8. pii: S0190-9622(20)30029-3. doi: 10.1016/j.jaad.2019.12.055. [Epub ahead of print]

PMID:
31926221
5.

Development and initial testing of a new instrument to measure the experience of eczema control in adults and children: Recap of atopic eczema (RECAP).

Howells LM, Chalmers JR, Gran S, Ahmed A, Apfelbacher C, Burton T, Howie L, Lawton S, Ridd MJ, Rogers NK, Sears AV, Spuls P, von Kobyletzki L, Thomas KS.

Br J Dermatol. 2019 Dec 3. doi: 10.1111/bjd.18780. [Epub ahead of print]

PMID:
31794074
6.

Protocol for an outcome assessor-blinded pilot randomised controlled trial of an ion-exchange water softener for the prevention of atopic eczema in neonates, with an embedded mechanistic study: the Softened Water for Eczema Prevention (SOFTER) trial.

Jabbar-Lopez ZK, Gurung N, Greenblatt D, Briley A, Chalmers JR, Thomas KS, Frost T, Kezic S, Common JEA, Kong HH, Segre JA, Danby S, Cork MJ, Peacock JL, Flohr C.

BMJ Open. 2019 Aug 20;9(8):e027168. doi: 10.1136/bmjopen-2018-027168.

7.

TEST (Trial of Eczema allergy Screening Tests): protocol for feasibility randomised controlled trial of allergy tests in children with eczema, including economic scoping and nested qualitative study.

Ridd MJ, Edwards L, Santer M, Chalmers JR, Waddell L, Marriage D, Muller I, Roberts K, Garfield K, Coast J, Selman L, Clement C, Shaw ARG, Angier E, Blair PS, Turner NL, Taylor J, Kai J, Boyle RJ.

BMJ Open. 2019 May 9;9(5):e028428. doi: 10.1136/bmjopen-2018-028428.

8.

Navigating the landscape of core outcome set development in dermatology.

Prinsen CAC, Spuls PI, Kottner J, Thomas KS, Apfelbacher C, Chalmers JR, Deckert S, Furue M, Gerbens L, Kirkham J, Simpson EL, Alam M, Balzer K, Beeckman D, Eleftheriadou V, Ezzedine K, Horbach SER, Ingram JR, Layton AM, Weller K, Wild T, Wolkerstorfer A, Williams HC, Schmitt J.

J Am Acad Dermatol. 2019 Jul;81(1):297-305. doi: 10.1016/j.jaad.2019.03.009. Epub 2019 Mar 13. Review.

PMID:
30878565
9.

The Burden of Childhood Atopic Dermatitis in the Primary Care Setting: A Report from the Meta-LARC Consortium.

Al-Naqeeb J, Danner S, Fagnan LJ, Ramsey K, Michaels L, Mitchell J, Branca K, Morris C, Nease DE Jr, Zittleman L, Levy B, Daly J, Hahn D, Dolor RJ, Williams HC, Chalmers JR, Hanifin J, Tofte S, Zuckerman KE, Hansis K, Gundersen M, Block J, Karr F, Dunbrasky S, Siebe K, Dillon K, Cibotti R, Lapidus J, Simpson EL.

J Am Board Fam Med. 2019 Mar-Apr;32(2):191-200. doi: 10.3122/jabfm.2019.02.180225.

10.

Defining and measuring 'eczema control': an international qualitative study to explore the views of those living with and treating atopic eczema.

Howells L, Thomas KS, Sears AV, Nasr I, Wollenberg A, Schuttelaar MLA, Romeijn GLE, Paller AS, Mueller K, Doytcheva K, Kataoka Y, Daguze J, Barbarot S, von Kobyletzki LB, Beckman L, Ratib S, Cowdell F, Santer M, Chalmers JR; long-term control of eczema working group for the HOME initiative.

J Eur Acad Dermatol Venereol. 2019 Jun;33(6):1124-1132. doi: 10.1111/jdv.15475. Epub 2019 Apr 8.

11.

Management of cellulitis: current practice and research questions.

Santer M, Lalonde A, Francis NA, Smart P, Hooper J, Teasdale E, Del Mar C, Chalmers JR, Thomas KS.

Br J Gen Pract. 2018 Dec;68(677):595-596. doi: 10.3399/bjgp18X700181. No abstract available.

12.

Towards a better understanding of outcome measurement instruments for atopic eczema.

Chalmers JR, Danby S.

Br J Dermatol. 2018 Aug;179(2):246-247. doi: 10.1111/bjd.16827. No abstract available.

PMID:
30141558
13.

Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative.

Grinich EE, Schmitt J, Küster D, Spuls PI, Williams HC, Chalmers JR, Thomas KS, Apfelbacher C, Prinsen CAC, Furue M, Stuart B, Carter B, Simpson EL.

Br J Dermatol. 2018 Aug;179(2):540-541. doi: 10.1111/bjd.16732. Epub 2018 Jun 25. No abstract available.

PMID:
29747242
14.

Report from the fifth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).

Chalmers JR, Thomas KS, Apfelbacher C, Williams HC, Prinsen CA, Spuls PI, Simpson E, Gerbens LAA, Boers M, Barbarot S, Stalder JF, Abuabara K, Aoki V, Ardeleanu M, Armstrong J, Bang B, Berents TL, Burton T, Butler L, Chubachi T, Cresswell-Melville A, DeLozier A, Eckert L, Eichenfield L, Flohr C, Futamura M, Gadkari A, Gjerde ES, van Halewijn KF, Hawkes C, Howells L, Howie L, Humphreys R, Ishii HA, Kataoka Y, Katayama I, Kouwenhoven W, Langan SM, Leshem YA, Merhand S, Mina-Osorio P, Murota H, Nakahara T, Nunes FP, Nygaard U, Nygårdas M, Ohya Y, Ono E, Rehbinder E, Rogers NK, Romeijn GLE, Schuttelaar MLA, Sears AV, Simpson MA, Singh JA, Srour J, Stuart B, Svensson Å, Talmo G, Talmo H, Teixeira HD, Thyssen JP, Todd G, Torchet F, Volke A, von Kobyletzki L, Weisshaar E, Wollenberg A, Zaniboni M.

Br J Dermatol. 2018 May;178(5):e332-e341. doi: 10.1111/bjd.16543. Epub 2018 Apr 19.

PMID:
29672835
15.

Home interventions and light therapy for the treatment of vitiligo (HI-Light Vitiligo Trial): study protocol for a randomised controlled trial.

Haines RH, Thomas KS, Montgomery AA, Ravenscroft JC, Akram P, Chalmers JR, Whitham D, Duley L, Eleftheriadou V, Meakin G, Mitchell EJ, White J, Rogers A, Sach T, Santer M, Tan W, Hepburn T, Williams HC, Batchelor J.

BMJ Open. 2018 Apr 3;8(4):e018649. doi: 10.1136/bmjopen-2017-018649.

16.

How should minimally important change scores for the Patient-Oriented Eczema Measure be interpreted? A validation using varied methods.

Howells L, Ratib S, Chalmers JR, Bradshaw L, Thomas KS; CLOTHES trial team.

Br J Dermatol. 2018 May;178(5):1135-1142. doi: 10.1111/bjd.16367. Epub 2018 Apr 17.

17.
18.

Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial.

Mason JM, Chalmers JR, Godec T, Nunn AJ, Kirtschig G, Wojnarowska F, Childs M, Whitham D, Schmidt E, Harman K, Walton S, Chapman A, Williams HC; U.K. Dermatology Clinical Trials Network BLISTER Study Group.

Br J Dermatol. 2018 Feb;178(2):415-423. doi: 10.1111/bjd.16006. Epub 2018 Jan 15.

19.

The BLISTER study: possible overestimation of tetracycline efficacy - Authors' reply.

Williams HC, Chalmers JR, Nunn AJ, Kirtschig G, Schmidt E.

Lancet. 2017 Aug 19;390(10096):735-736. doi: 10.1016/S0140-6736(17)31790-7. No abstract available.

PMID:
28831990
20.

Effectiveness and cost-effectiveness of daily all-over-body application of emollient during the first year of life for preventing atopic eczema in high-risk children (The BEEP trial): protocol for a randomised controlled trial.

Chalmers JR, Haines RH, Mitchell EJ, Thomas KS, Brown SJ, Ridd M, Lawton S, Simpson EL, Cork MJ, Sach TH, Bradshaw LE, Montgomery AA, Boyle RJ, Williams HC.

Trials. 2017 Jul 21;18(1):343. doi: 10.1186/s13063-017-2031-3.

21.

Identifying priority areas for research into the diagnosis, treatment and prevention of cellulitis (erysipelas): results of a James Lind Alliance Priority Setting Partnership.

Thomas KS, Brindle R, Chalmers JR, Gamble B, Francis NA, Hardy D, Hooper J, Keeley V, Levell NJ, McPhee M, Metcalf L, Santer M, Tarpey M, Smart P, Wallace A, Wilkes S.

Br J Dermatol. 2017 Aug;177(2):541-543. doi: 10.1111/bjd.15634. Epub 2017 Jun 14. No abstract available.

PMID:
28477399
22.

A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial.

Chalmers JR, Wojnarowska F, Kirtschig G, Mason J, Childs M, Whitham D, Harman K, Chapman A, Walton S, Schmidt E, Godec TR, Nunn AJ, Williams HC.

Health Technol Assess. 2017 Mar;21(10):1-90. doi: 10.3310/hta21100.

23.

Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial.

Williams HC, Wojnarowska F, Kirtschig G, Mason J, Godec TR, Schmidt E, Chalmers JR, Childs M, Walton S, Harman K, Chapman A, Whitham D, Nunn AJ; UK Dermatology Clinical Trials Network BLISTER Study Group.

Lancet. 2017 Apr 22;389(10079):1630-1638. doi: 10.1016/S0140-6736(17)30560-3. Epub 2017 Mar 6. Erratum in: Lancet. 2017 Oct 28;390(10106):1948.

24.

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease.

Thomas KS, Batchelor JM, Bath-Hextall F, Chalmers JR, Clarke T, Crowe S, Delamere FM, Eleftheriadou V, Evans N, Firkins L, Greenlaw N, Lansbury L, Lawton S, Layfield C, Leonardi-Bee J, Mason J, Mitchell E, Nankervis H, Norrie J, Nunn A, Ormerod AD, Patel R, Perkins W, Ravenscroft JC, Schmitt J, Simpson E, Whitton ME, Williams HC.

Southampton (UK): NIHR Journals Library; 2016 Dec.

25.

Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement.

Spuls PI, Gerbens LAA, Simpson E, Apfelbacher CJ, Chalmers JR, Thomas KS, Prinsen CAC, von Kobyletzki LB, Singh JA, Williams HC, Schmitt J; HOME initiative collaborators.

Br J Dermatol. 2017 Apr;176(4):979-984. doi: 10.1111/bjd.15179. Epub 2017 Mar 2. Review.

PMID:
27858989
26.

Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative).

Chalmers JR, Simpson E, Apfelbacher CJ, Thomas KS, von Kobyletzki L, Schmitt J, Singh JA, Svensson Å, Williams HC, Abuabara K, Aoki V, Ardeleanu M, Awici-Rasmussen M, Barbarot S, Berents TL, Block J, Bragg A, Burton T, Bjerring Clemmensen KK, Creswell-Melville A, Dinesen M, Drucker A, Eckert L, Flohr C, Garg M, Gerbens LA, Graff AL, Hanifin J, Heinl D, Humphreys R, Ishii HA, Kataoka Y, Leshem YA, Marquort B, Massuel MA, Merhand S, Mizutani H, Murota H, Murrell DF, Nakahara T, Nasr I, Nograles K, Ohya Y, Osterloh I, Pander J, Prinsen C, Purkins L, Ridd M, Sach T, Schuttelaar ML, Shindo S, Smirnova J, Sulzer A, Synnøve Gjerde E, Takaoka R, Vestby Talmo H, Tauber M, Torchet F, Volke A, Wahlgren CF, Weidinger S, Weisshaar E, Wollenberg A, Yamaga K, Zhao CY, Spuls PI.

Br J Dermatol. 2016 Jul;175(1):69-79. doi: 10.1111/bjd.14773. Epub 2016 Jul 19.

PMID:
27436240
27.

Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review.

Gerbens LA, Prinsen CA, Chalmers JR, Drucker AM, von Kobyletzki LB, Limpens J, Nankervis H, Svensson Å, Terwee CB, Zhang J, Apfelbacher CJ, Spuls PI; Harmonising Outcome Measures for Eczema (HOME) initiative.

Allergy. 2017 Jan;72(1):146-163. doi: 10.1111/all.12959. Epub 2016 Jul 13. Review.

PMID:
27322918
28.

What Factors are Important to Patients when Assessing Treatment Response: An International Cross-sectional Survey.

von Kobyletzki LB, Thomas KS, Schmitt J, Chalmers JR, Deckert S, Aoki V, Weisshaar E, Ojo JA, Svensson Å.

Acta Derm Venereol. 2017 Jan 4;97(1):86-90. doi: 10.2340/00015555-2480.

29.

Reporting of symptoms in randomized controlled trials of atopic eczema treatments: a systematic review.

Gerbens LA, Chalmers JR, Rogers NK, Nankervis H, Spuls PI; Harmonising Outcome Measures for Eczema (HOME) initiative.

Br J Dermatol. 2016 Oct;175(4):678-86. doi: 10.1111/bjd.14588. Epub 2016 Jul 28. Review.

PMID:
27012805
30.

Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review.

Heinl D, Prinsen CA, Deckert S, Chalmers JR, Drucker AM, Ofenloch R, Humphreys R, Sach T, Chamlin SL, Schmitt J, Apfelbacher C.

Allergy. 2016 Mar;71(3):358-70. doi: 10.1111/all.12806. Epub 2015 Dec 16. Review.

PMID:
26564008
31.

How to teleconference effectively.

Williams HC, Chalmers JR.

Br J Dermatol. 2015 Sep;173(3):806-10. doi: 10.1111/bjd.13952.

PMID:
26404576
32.

Clearing up misunderstandings around core outcomes for atopic dermatitis.

Williams HC, Apfelbacher C, Chalmers JR, Schmitt J, Simpson EL, Spuls PI, Thomas KS.

Br J Dermatol. 2015 Aug;173(2):623-4; discussion 624-5. doi: 10.1111/bjd.13787. Epub 2015 Jul 14. No abstract available.

PMID:
25819300
33.

A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial.

Chalmers JR, Wojnarowska F, Kirtschig G, Nunn AJ, Bratton DJ, Mason J, Foster KA, Whitham D, Williams HC; BLISTER study group.

Br J Dermatol. 2015 Jul;173(1):227-34. doi: 10.1111/bjd.13729. Epub 2015 May 26.

PMID:
25683592
34.

Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention.

Simpson EL, Chalmers JR, Hanifin JM, Thomas KS, Cork MJ, McLean WH, Brown SJ, Chen Z, Chen Y, Williams HC.

J Allergy Clin Immunol. 2014 Oct;134(4):818-23. doi: 10.1016/j.jaci.2014.08.005.

35.

Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME).

Chalmers JR, Schmitt J, Apfelbacher C, Dohil M, Eichenfield LF, Simpson EL, Singh J, Spuls P, Thomas KS, Admani S, Aoki V, Ardeleanu M, Barbarot S, Berger T, Bergman JN, Block J, Borok N, Burton T, Chamlin SL, Deckert S, DeKlotz CC, Graff LB, Hanifin JM, Hebert AA, Humphreys R, Katoh N, Kisa RM, Margolis DJ, Merhand S, Minnillo R, Mizutani H, Nankervis H, Ohya Y, Rodgers P, Schram ME, Stalder JF, Svensson A, Takaoka R, Teper A, Tom WL, von Kobyletzki L, Weisshaar E, Zelt S, Williams HC.

Br J Dermatol. 2014 Dec;171(6):1318-25. doi: 10.1111/bjd.13237. Epub 2014 Nov 14.

36.

Prophylactic antibiotics to prevent cellulitis of the leg: economic analysis of the PATCH I & II trials.

Mason JM, Thomas KS, Crook AM, Foster KA, Chalmers JR, Nunn AJ, Williams HC.

PLoS One. 2014 Feb 14;9(2):e82694. doi: 10.1371/journal.pone.0082694. eCollection 2014.

37.

Implementation of computerized cumulative acetaminophen dose tracking.

Hooley JM, Chalmers JR.

Am J Health Syst Pharm. 2014 Feb 1;71(3):188-9. doi: 10.2146/ajhp130240. No abstract available.

PMID:
24429010
38.

Penicillin to prevent recurrent leg cellulitis.

Thomas KS, Crook AM, Nunn AJ, Foster KA, Mason JM, Chalmers JR, Nasr IS, Brindle RJ, English J, Meredith SK, Reynolds NJ, de Berker D, Mortimer PS, Williams HC; U.K. Dermatology Clinical Trials Network's PATCH I Trial Team.

N Engl J Med. 2013 May 2;368(18):1695-703. doi: 10.1056/NEJMoa1206300.

39.

Prevention of atopic dermatitis.

Williams HC, Chalmers JR, Simpson EL.

F1000 Med Rep. 2012;4:24. doi: 10.3410/M4-24. Epub 2012 Dec 3.

40.

Overview of Reviews The prevention of eczema in infants and children: an overview of Cochrane and non-Cochrane reviews.

Foisy M, Boyle RJ, Chalmers JR, Simpson EL, Williams HC.

Evid Based Child Health. 2011 Sep;6(5):1322-1339. Epub 2011 Sep 8.

41.

How should an incident case of atopic dermatitis be defined? A systematic review of primary prevention studies.

Simpson EL, Keck LE, Chalmers JR, Williams HC.

J Allergy Clin Immunol. 2012 Jul;130(1):137-44. doi: 10.1016/j.jaci.2012.01.075. Epub 2012 Mar 15. Review.

42.

The UK clinical research network--has it been a success for dermatology clinical trials?

Thomas KS, Koller K, Foster K, Perdue J, Charlesworth L, Chalmers JR.

Trials. 2011 Jun 16;12:153. doi: 10.1186/1745-6215-12-153.

43.

To freeze or not to freeze: a cost-effectiveness analysis of wart treatment.

Keogh-Brown MR, Fordham RJ, Thomas KS, Bachmann MO, Holland RC, Avery AJ, Armstrong SJ, Chalmers JR, Howe A, Rodgers S, Williams HC, Harvey I.

Br J Dermatol. 2007 Apr;156(4):687-92. Epub 2007 Feb 27. Review.

PMID:
17326748
44.

Effectiveness and cost-effectiveness of salicylic acid and cryotherapy for cutaneous warts. An economic decision model.

Thomas KS, Keogh-Brown MR, Chalmers JR, Fordham RJ, Holland RC, Armstrong SJ, Bachmann MO, Howe AH, Rodgers S, Avery AJ, Harvey I, Williams HC.

Health Technol Assess. 2006 Aug;10(25):iii, ix-87.

45.

Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.

Chalmers JR, Bobek MB, Militello MA.

Am J Health Syst Pharm. 2001 Mar 15;58(6):504-6. Erratum in: Am J Health Syst Pharm.2003 Jun 1;60(11):1095-6.

PMID:
11286148

Supplemental Content

Loading ...
Support Center